Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.38 |
| ▸ | NT5E | P21589 | 2/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835020 | 0.86 | ST6GAL1 (0.43) | ST6GAL1NT5E | |
| SCHEMBL6234928 | 0.85 | ST6GAL1 (0.35) | ST6GAL1 | |
| SCHEMBL6236139 | 0.85 | POLB (0.36) | ST6GAL1 | |
| SCHEMBL7074770 | 0.84 | P2RX3 (0.41) | — | |
| SCHEMBL4458009 | 0.79 | ST6GAL1 (0.42) | ST6GAL1NT5E | |
| SCHEMBL6833762 | 0.78 | ST6GAL1 (0.35) | ST6GAL1 | |
| SCHEMBL6835037 | 0.78 | ST6GAL1 (0.35) | ST6GAL1 | |
| SCHEMBL6231869 | 0.78 | TAAR1 (0.41) | NT5E | |
| SCHEMBL10693710 | 0.78 | ST6GAL1 (0.38) | ST6GAL1NT5E | |
| SCHEMBL8467590 | 0.77 | NT5E (0.40) | ST6GAL1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | ST6GAL1 2918/4885NT5E 27/4885P2RY6 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.